Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 15/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | XPO1 | O14980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513177 | 0.88 | HDAC4 (0.53) | GRM5KMT2AHDAC4 | |
| SCHEMBL17115024 | 0.81 | MAPT (0.56) | KCNH2GRM5KMT2AHDAC4 | |
| SCHEMBL513744 | 0.79 | GBA1 (0.51) | GRM5HDAC4 | |
| SCHEMBL6293413 | 0.77 | GRM5 (0.50) | GRM5KMT2A | |
| SCHEMBL513293 | 0.76 | GRM5 (0.46) | GRM5KMT2AHDAC4 | |
| SCHEMBL27621215 | 0.76 | STS (0.52) | GRM5KMT2AUSP30XPO1 | |
| SCHEMBL4226736 | 0.75 | NPC1 (0.44) | GRM5KMT2A | |
| SCHEMBL513294 | 0.74 | HTR7 (0.51) | GRM5KMT2A | |
| SCHEMBL5485886 | 0.73 | GRM5 (0.52) | GRM5 | |
| SCHEMBL514361 | 0.73 | GRM5 (0.41) | GRM5KMT2AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | KCNH2 498/4885GRM5 2/4885KMT2A 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.